Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHANIE V BLANK

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1043211626
CMS profile
46868
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$23.98

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $23.98 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Intuitive Surgical, Inc. $23.98 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHANIE V BLANK

NPI 1043211626 · CMS profile ID 46868

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043211626?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043211626?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043211626?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1043211626?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $23.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Intuitive Surgical, Inc. $11.9910/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706525481 CMS
Intuitive Surgical, Inc. $11.9910/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706525475 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23.98 2
PY2021 $86.27 2
PY2022 $37.23 1
PY2025 $153.17 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $226,900.10 37
PY2024 Principal investigator $170,088.03 42
PY2023 Principal investigator $268,544.71 34
PY2022 Principal investigator $532,628.40 36
PY2021 Recipient $460.98 2
PY2021 Principal investigator $559,085.02 64
PY2020 Principal investigator $916,005.72 160
PY2019 Principal investigator $645,377.42 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

103 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $6,291.00 12/20/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128983
Principal investigator 1 Merck Sharp & Dohme Corporation $4,175.00 12/19/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691504803
Principal investigator 1 Merck Sharp & Dohme Corporation $845.00 12/19/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691504809
Principal investigator 1 TESARO, Inc. $40,143.60 12/18/2019 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689414535
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 12/16/2019 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691516769
Principal investigator 1 EMD Serono, Inc. $2,025.00 12/13/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS201943-0029 No dispute reported 06/30/2026 703034697
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 12/12/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691491379
Principal investigator 1 Merck Sharp & Dohme Corporation $6,525.00 12/12/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691504807
Principal investigator 1 Seattle Genetics, Inc. $845.00 12/11/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820457
Principal investigator 1 Genentech, Inc. $6,685.24 12/05/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128977
Principal investigator 1 Merck Sharp & Dohme Corporation $3,198.15 12/04/2019 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691498395
Principal investigator 1 Seattle Genetics, Inc. $525.00 12/04/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820455
Principal investigator 1 EMD Serono, Inc. $845.00 11/22/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS201943-0029 No dispute reported 06/30/2026 703033277
Principal investigator 1 Merck Sharp & Dohme Corporation $1,542.78 11/22/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691537707
Principal investigator 1 Merck Sharp & Dohme Corporation $1,542.78 11/22/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691537709
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 11/22/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691537889
Principal investigator 1 Seattle Genetics, Inc. $1,825.00 11/20/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820453
Principal investigator 1 Merck Sharp & Dohme Corporation $2,620.35 11/15/2019 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691498391
Principal investigator 1 Seattle Genetics, Inc. $776.25 11/13/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820463
Principal investigator 1 Genentech, Inc. $841.00 11/12/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128973
Principal investigator 1 Merck Sharp & Dohme Corporation $12,930.00 11/12/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691448421
Principal investigator 1 Seattle Genetics, Inc. $337.50 11/06/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820465
Principal investigator 1 Genentech, Inc. $4,741.00 11/04/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128967
Principal investigator 1 Seattle Genetics, Inc. $38,399.40 10/21/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820467
Principal investigator 1 Merck Sharp & Dohme Corporation $3,030.75 10/09/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691481177
Principal investigator 1 Seattle Genetics, Inc. $141.40 10/09/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820459
Principal investigator 1 Seattle Genetics, Inc. $273.90 10/09/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 678820461
Principal investigator 1 Genentech, Inc. $750.00 10/03/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128963
Principal investigator 1 Merck Sharp & Dohme Corporation $337.50 10/02/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691485085
Principal investigator 1 Merck Sharp & Dohme Corporation $337.50 10/02/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691485087
Principal investigator 1 Genentech, Inc. $3,342.62 10/01/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128957
Principal investigator 1 Genentech, Inc. $1,411.00 09/27/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128953
Principal investigator 1 Merck Sharp & Dohme Corporation $525.00 09/25/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691408943
Principal investigator 1 Merck Sharp & Dohme Corporation $845.00 09/25/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691408961
Principal investigator 1 Genentech, Inc. $6,685.24 09/20/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128947
Principal investigator 1 Merck Sharp & Dohme Corporation $2,047.92 09/20/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691407465
Principal investigator 1 Merck Sharp & Dohme Corporation $26.60 09/18/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691367031
Principal investigator 1 Genentech, Inc. $7,107.24 09/13/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128941
Principal investigator 1 Seattle Genetics, Inc. $337.50 09/11/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078967
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 09/10/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691439057
Principal investigator 1 Merck Sharp & Dohme Corporation $845.00 09/09/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691408965
Principal investigator 1 Merck Sharp & Dohme Corporation $2,882.25 09/09/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691409799
Principal investigator 1 Merck Sharp & Dohme Corporation $2,911.95 09/09/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691418533
Principal investigator 1 TESARO, Inc. $26,762.40 08/29/2019 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689412875
Principal investigator 1 Seattle Genetics, Inc. $1,350.00 08/28/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078947
Principal investigator 1 Seattle Genetics, Inc. $110.10 08/28/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078965
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 08/27/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691438605
Principal investigator 1 EMD Serono, Inc. $2,025.00 08/26/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS201943-0029 No dispute reported 06/30/2026 703034705
Principal investigator 1 Merck Sharp & Dohme Corporation $2,772.90 08/14/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691383117
Principal investigator 1 Seattle Genetics, Inc. $3,909.10 08/14/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078961
Principal investigator 1 Seattle Genetics, Inc. $166.79 08/14/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078963
Principal investigator 1 Seattle Genetics, Inc. $2,025.00 08/07/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078959
Principal investigator 1 TESARO, Inc. $26,762.40 07/29/2019 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689412379
Principal investigator 1 EMD Serono, Inc. $845.00 07/24/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS201943-0029 No dispute reported 06/30/2026 703033293
Principal investigator 1 TESARO, Inc. $1,500.00 07/18/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689412323
Principal investigator 1 TESARO, Inc. $845.00 07/18/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689412327
Principal investigator 1 Merck Sharp & Dohme Corporation $1,345.35 07/11/2019 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691474513
Principal investigator 1 Merck Sharp & Dohme Corporation $3,350.70 07/10/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691383295
Principal investigator 1 Merck Sharp & Dohme Corporation $845.00 07/10/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691383379
Principal investigator 1 Seattle Genetics, Inc. $1,011.62 07/10/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078957
Principal investigator 1 Merck Sharp & Dohme Corporation $960.52 07/08/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691383415
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 07/02/2019 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 691343815
Principal investigator 1 Seattle Genetics, Inc. $845.00 07/02/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078949
Principal investigator 1 Merck Sharp & Dohme Corporation $3,121.40 06/28/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691335233
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 06/28/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691350329
Principal investigator 1 Seattle Genetics, Inc. $845.00 06/26/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078951
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 06/24/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691440347
Principal investigator 1 Seattle Genetics, Inc. $525.00 06/19/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078943
Principal investigator 1 Seattle Genetics, Inc. $845.00 06/19/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078945
Principal investigator 1 EMD Serono, Inc. $845.00 06/12/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703033273
Principal investigator 1 EMD Serono, Inc. $1,000.00 06/12/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703033481
Principal investigator 1 Seattle Genetics, Inc. $845.00 06/12/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078941
Principal investigator 1 Seattle Genetics, Inc. $830.77 06/12/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078955
Principal investigator 1 Merck Sharp & Dohme Corporation $17,025.00 06/05/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691350033
Principal investigator 1 Merck Sharp & Dohme Corporation $7,000.00 06/05/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691350331
Principal investigator 1 Seattle Genetics, Inc. $1,988.96 06/05/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078953
Principal investigator 1 EMD Serono, Inc. $1,825.00 06/03/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703034535
Principal investigator 1 Merck Sharp & Dohme Corporation $4,868.45 05/31/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691316269
Principal investigator 1 Merck Sharp & Dohme Corporation $845.00 05/31/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691316277
Principal investigator 1 Merck Sharp & Dohme Corporation $3,500.00 05/31/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691317489
Principal investigator 1 Seattle Genetics, Inc. $845.00 05/29/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078937
Principal investigator 1 Seattle Genetics, Inc. $1,825.00 05/29/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078939
Principal investigator 1 Seattle Genetics, Inc. $18,950.00 05/22/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078935
Principal investigator 1 Seattle Genetics, Inc. $7,000.00 05/15/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078933
Principal investigator 1 Genentech, Inc. $6,861.00 05/13/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128923
Principal investigator 1 TESARO, Inc. $13,035.00 05/10/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689411221
Principal investigator 1 EMD Serono, Inc. $845.00 05/02/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703033267
Principal investigator 1 EMD Serono, Inc. $2,000.00 04/23/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703034641
Principal investigator 1 EMD Serono, Inc. $3,500.00 04/23/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703035381
Principal investigator 1 EMD Serono, Inc. $8,275.00 04/23/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703036299
Principal investigator 1 EMD Serono, Inc. $15,000.00 04/23/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK, LLC
MS 201943-0029 No dispute reported 06/30/2026 703036779
Principal investigator 1 Merck Sharp & Dohme Corporation $27,065.60 04/22/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691439060
Principal investigator 1 TESARO, Inc. $13,275.00 04/16/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST No dispute reported 06/30/2026 689410865
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 04/12/2019 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 691370683
Principal investigator 1 AstraZeneca UK Limited $500.00 03/28/2019 Non-covered Recipient Entity
New York Univ School Of Med
Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens No dispute reported 06/30/2026 685000711
Principal investigator 1 Seattle Genetics, Inc. $525.00 03/20/2019 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 709078931
Principal investigator 1 Genentech, Inc. $8,750.00 03/12/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128917
Principal investigator 1 Genentech, Inc. $11,250.00 02/25/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128907
Principal investigator 1 Genentech, Inc. $187.50 02/25/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128913
Principal investigator 1 Genentech, Inc. $22,096.00 02/12/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128937
Principal investigator 1 Genentech, Inc. $13,000.00 02/01/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128927
Principal investigator 1 Genentech, Inc. $1,000.00 02/01/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128931
Principal investigator 1 Genentech, Inc. $80,000.00 01/17/2019 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857128903